Apabetalone in addition to high-intensity statin therapy for preventing major adverse cardiac events in high-risk cardiovascular disease patients with type 2 diabetes mellitus
Apabetalone is in clinical development for the prevention of major adverse cardiac events (including heart attack or stroke) for patients with a high risk of cardiovascular disease, type 2 diabetes mellitus and a low high-density lipoprotein (HDL). People with type 2 diabetes have a higher risk of cardiovascular disease, as high levels of glucose in the blood can damage the walls of the arteries, making them more likely to develop fatty deposits (atheroma). These atheroma can narrow the arteries, reducing the amount of oxygen-rich blood getting to the heart, or can break off and cause a blood clot, which may result in a heart attack or stroke.
Apabetalone is the first product developed to inhibit BET proteins. These BET proteins can control the activity of cells and make them produce proteins that cause inflammation. By inhibiting the BET proteins the production of inflammatory proteins is reduced. Apabetalone also increases production of high density lipoproteins which removes excess cholesterol, reducing the risk of cardiovascular disease. Apabetalone has the potential to affect multiple processes which contribute to cardiovascular disease, with the overall result of reducing the risk of a major adverse cardiac event in diabetic patients. If licensed, apabetalone may offer an additional preventive treatment option for major adverse cardiac events in patients with type 2 diabetes mellitus, high-risk a high risk of cardiovascular disease and low HDL.